Compare AIDX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | CALC |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | AIDX | CALC |
|---|---|---|
| Price | $0.95 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 241.0K | ★ 296.5K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.46 |
| 52 Week High | $14.09 | $7.20 |
| Indicator | AIDX | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 58.19 |
| Support Level | N/A | $0.52 |
| Resistance Level | $1.66 | $0.93 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 51.61 | 50.12 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.